Molecular Classification of Hormone Sensitive and Castration Resistant prostate cancer, using non-negative matrix factorization molecular subtyping
|Study ID||Alternative Stable ID||Type|
We aim to identify molecular subtypes of prostate cancer using consensus non-negative matrix factorization and correlate these with existing biomarkers to inform future immunotherapeutic strategies.
Study Datasets 3 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Bulk tumor RNAseq FASTQ files from 124 samples from patients with hormone sensitive or castration resistant prostate cancer.
|Illumina HiSeq 4000||124|
Clinical data from this cohort of patients, including hormone sensitive or castration resistant prostate cancer, overall survival, NMF subtypes, tumor TMB, prior treatment status, PD-L1 IC and TC scores from SP142 and SP263 as well as percentage of CD8 IHC at tumor center.
Raw count matrix of the 124 bulk tumor RNAseq samples from patients with hormone sensitive or castration resistant prostate cancer.